You are here: Industry Insights > Rybelsus

News List

Novo Nordisk set to acquire Emisphere for $1.8 billion europeanpharmaceuticalreview
November 13, 2020
Following approval by Emisphere shareholders, Novo Nordisk will acquire the company for a total of $1.8 billion.
UK launch for Novo's new diabetes pill pharmatimes
September 02, 2020
Novo Nordisk has launched in the UK the first 'protein in a pill' treatment for type II diabetes.
EU nod for Novo's diabetes drug Rybelsus pharmatimes
April 07, 2020
Novo Nordisk's Rybelsus (oral semaglutide) has won European approval for type II diabetes, offering adults a new treatment option as the first and only oral glucagon-like-peptide-1 (GLP-1) receptor agonist.
FDA Approves New Indication for Ozempic, Updated Rybelsus Prescribing Information americanpharmaceuticalreview
January 19, 2020
Novo Nordisk announced the U.S. Food and Drug Administration (FDA) has approved a new indication for Ozempic® (semaglutide) injection 0.5 mg or 1 mg to reduce the risk of major adverse cardiovascular events (MACE) such as heart attack, stroke ...
Novo's Rybelsus, check. Here are the major launches coming up next fiercepharma
September 26, 2019
The drug drew the interest of Bristol-Myers Squibb, which is set to swallow Celgene in a megamerger. Luspatercept represents a "high value near-term asset," BMS has said.
FDA approves oral semaglutide Rybelsus to treat type 2 diabetes pharmaceutical-technology
September 26, 2019
FDA approval comes from results from ten PIONEER clinical trials conducted in a total of 9,543 adult type 2 diabetes patients.
First oral GLP-1 treatment for type 2 diabetes approved europeanpharmaceuticalreview
September 24, 2019
With the approval of the treatment, Rybelsus, there is a new option for treating type 2 diabetes without injections.
FDA Approves Rybelsus (semaglutide), the First Oral GLP-1 Analog Treatment for Adults with Type 2 Diabetes drugs
September 23, 2019
Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Rybelsus (semaglutide) tablets 7 mg or 14 mg for adults with type 2 diabetes that along with diet and exercise may improve blood sugar (glucose).